DK2892535T3 - Fremgangsmåde til adjuverende cancerbehandling - Google Patents

Fremgangsmåde til adjuverende cancerbehandling Download PDF

Info

Publication number: DK2892535T3
Authority: DK; Denmark
Prior art keywords: procedure; cancer treatment; adjuvant cancer; adjuvant; treatment
Prior art date: 2012-09-04

Application number

DK13835019.4T

Other languages

English (en)

Inventor

Sylvie Laquerre

Peter F Lebowitz

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-04

Filing date

2013-08-30

Publication date

2022-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2892535(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-30 Application filed by Novartis Ag filed Critical Novartis Ag

2022-01-03 Application granted granted Critical

2022-01-03 Publication of DK2892535T3 publication Critical patent/DK2892535T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK13835019.4T 2012-09-04 2013-08-30 Fremgangsmåde til adjuverende cancerbehandling DK2892535T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261696375P	2012-09-04	2012-09-04
PCT/US2013/057432 WO2014039375A1 (en)	2012-09-04	2013-08-30	Method of adjuvant cancer treatment

Publications (1)

Publication Number	Publication Date
DK2892535T3 true DK2892535T3 (da)	2022-01-03

Family

ID=50237545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13835019.4T DK2892535T3 (da)	2012-09-04	2013-08-30	Fremgangsmåde til adjuverende cancerbehandling

Country Status (20)

Country	Link
US (6)	US20150216868A1 (da)
EP (2)	EP3981408A1 (da)
JP (3)	JP2015527374A (da)
KR (1)	KR102134585B1 (da)
CN (2)	CN107308164A (da)
AU (2)	AU2013313050A1 (da)
BR (1)	BR112015004578A2 (da)
CA (1)	CA2882437C (da)
CY (1)	CY1124812T1 (da)
DK (1)	DK2892535T3 (da)
ES (1)	ES2900825T3 (da)
HR (1)	HRP20211817T1 (da)
HU (1)	HUE056646T2 (da)
IN (1)	IN2015KN00449A (da)
LT (1)	LT2892535T (da)
PL (1)	PL2892535T3 (da)
PT (1)	PT2892535T (da)
RU (1)	RU2640180C2 (da)
SI (1)	SI2892535T1 (da)
WO (1)	WO2014039375A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2013313050A1 (en)	2012-09-04	2015-03-26	Novartis Ag	Method of adjuvant cancer treatment
SG10201804519RA (en)	2013-12-28	2018-07-30	Guardant Health Inc	Methods and systems for detecting genetic variants
KR102341660B1 (ko)	2016-09-19	2021-12-23	노파르티스 아게	Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
CN110494166B (zh)	2017-05-02	2022-11-08	诺华股份有限公司	组合疗法
US11890286B2 (en) *	2018-04-17	2024-02-06	The University Of Chicago	Methods and compositions for treating cancer
CN109106893B (zh) *	2018-11-12	2021-04-20	上海市中西医结合医院	一种调节肠道屏障功能的中药复方制剂及其制备方法
BR112021022335A2 (pt)	2019-05-13	2021-12-28	Novartis Ag	Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
CN118767143A (zh) *	2019-12-12	2024-10-15	听治疗有限责任公司	用于预防和治疗听力损失的组合物和方法
EP4444299A1 (en)	2021-12-06	2024-10-16	My Personal Therapeutics Ltd	A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA06014478A (es)	2004-06-11	2007-03-21	Japan Tobacco Inc	Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
CA2598239C (en) *	2005-02-18	2019-10-29	Abraxis Bioscience, Inc.	Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
SI2488033T1 (sl) *	2009-10-16	2019-10-30	Novartis Ag	Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF
US20130004481A1 (en) *	2011-01-12	2013-01-03	Boehringer Ingelheim International Gmbh	Anticancer therapy
AU2013313050A1 (en)	2012-09-04	2015-03-26	Novartis Ag	Method of adjuvant cancer treatment

2013
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en not_active Ceased
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active Active
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1124812T1 (el)	2022-11-25
HUE056646T2 (hu)	2022-02-28
LT2892535T (lt)	2021-12-10
RU2015105821A (ru)	2016-10-20
JP6684941B2 (ja)	2020-04-22
JP2019142899A (ja)	2019-08-29
JP2015527374A (ja)	2015-09-17
JP6511117B2 (ja)	2019-05-15
US20170202842A1 (en)	2017-07-20
CA2882437A1 (en)	2014-03-13
AU2013313050A1 (en)	2015-03-26
KR102134585B1 (ko)	2020-07-17
PT2892535T (pt)	2021-12-15
AU2016244279A1 (en)	2016-11-03
US20180338979A1 (en)	2018-11-29
AU2016244279B2 (en)	2018-01-04
US10869869B2 (en)	2020-12-22
IN2015KN00449A (da)	2015-07-17
CN107308164A (zh)	2017-11-03
BR112015004578A2 (pt)	2017-07-04
KR20150047619A (ko)	2015-05-04
SI2892535T1 (sl)	2022-01-31
US20200054641A1 (en)	2020-02-20
US20210060021A1 (en)	2021-03-04
ES2900825T3 (es)	2022-03-18
CN104582706A (zh)	2015-04-29
PL2892535T3 (pl)	2022-01-31
JP2018058859A (ja)	2018-04-12
WO2014039375A1 (en)	2014-03-13
EP3981408A1 (en)	2022-04-13
HRP20211817T1 (hr)	2022-03-04
HK1206642A1 (en)	2016-01-15
US20150216868A1 (en)	2015-08-06
CA2882437C (en)	2021-03-02
EP2892535A1 (en)	2015-07-15
US20230330091A1 (en)	2023-10-19
EP2892535A4 (en)	2016-04-13
EP2892535B1 (en)	2021-09-22
RU2640180C2 (ru)	2017-12-26

Publication	Publication Date	Title
IL289300A (en)	2022-02-01	Combination therapy for treating cancer
IL267242B (en)	2020-08-31	Cancer treatment
DK2897620T3 (da)	2020-08-17	Fremgangsmåde til behandling af cancer
BR112014032105A2 (pt)	2017-08-01	método para o tratamento de câncer
LT2707030T (lt)	2020-07-10	Vėžio gydymas
BR112014007603A2 (pt)	2017-06-13	métodos de tratamento do câncer
HUE057061T2 (hu)	2022-04-28	Kombinációs terápia rák kezelésére
HUE046790T2 (hu)	2020-03-30	A rák kezelésének módszerei
HUE046667T2 (hu)	2020-03-30	Rák kombinatív kezelése
HUE047198T2 (hu)	2020-04-28	Fitokannabinoidok emlõrák kezelésére
HUE045314T2 (hu)	2019-12-30	Kombinációs terápia rák kezelésére
BR112014012880A2 (pt)	2017-06-13	tratamento imunogênico do câncer
PL2739153T3 (pl)	2019-04-30	Leczenie raka sutka
BR112014031806A2 (pt)	2017-08-29	método para tratamento de câncer positivo para gd2
DK2892535T3 (da)	2022-01-03	Fremgangsmåde til adjuverende cancerbehandling
LT2914254T (lt)	2020-04-27	Kombinacinės terapijos chemoresistencinių vėžių gydymui
HRP20180670T1 (hr)	2018-07-13	Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
DK2849760T3 (da)	2020-02-03	Fremgangsmåder til oligonukleotid-chelatkompleks
DK3290035T3 (da)	2019-08-05	Procaspase-kombinationsterapi til behandling af cancer
DK2825558T3 (da)	2019-07-22	Kombinationsterapi til behandling af ovariecancer
SMT201600235B (it)	2016-08-31	Predittori per il trattamento del cancro
EP2789306A4 (en)	2015-11-04	TREATMENT SYSTEM
DK2802351T3 (da)	2019-05-13	Midler til behandling af triple-negativ brystkræft
EP2804626A4 (en)	2015-08-26	VACCINE BASED ON AUTOLOGOUS CANCER CELLS
DK2872176T3 (en)	2017-06-19	Cancer treatment